Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Neurosci ; 17(12): 2593-601, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12823466

RESUMO

Various studies demonstrated that the neurotransmitter norepinephrine (NE) plays a relevant role in modulating seizures; in particular, a powerful effect consists in delaying the kindling of limbic areas such as the amygdala and hippocampus. Given the rich NE innervation of limbic regions, we selected a sensitive trigger area, the anterior piriform cortex, to test whether previous loss of noradrenergic terminals modifies sporadic seizures in rats. The damage to locus coeruleus terminals was produced by using the selective neurotoxin N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4, 60 mg/kg i.p.). In intact rats, bicuculline (a GABA-A antagonist, 118 pmol) microinfused into this area produced sporadic seizures, while in rats previously injected with DSP-4, bicuculline determined long-lasting self-sustaining status epilepticus. In intact rats, sporadic seizures were accompanied by a marked increase in norepinephrine release in the contralateral piriform cortex, while in locus coeruleus-lesioned rats this phenomenon was attenuated. While bicuculline-induced sporadic seizures were prevented by the focal infusion of amino-7-phosphonoheptanoic acid (AP-7, a selective NMDA antagonist), or 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulphonamide (NBQX, a selective non-NMDA antagonist), status epilepticus obtained in norepinephrine-lesioned rats was insensitive to AP-7 but was still inhibited by NBQX. By using fluorescent staining for damaged (Fluoro-Jade B) and intact (DAPI) neurons, as well as cresyl violet, we found that rats undergoing status epilepticus developed neuronal loss in various limbic regions. This study demonstrates a powerful effect of noradrenergic terminals in regulating the onset of limbic status epilepticus and its sensitivity to specific glutamate antagonists.


Assuntos
Excitação Neurológica/metabolismo , Locus Cerúleo/lesões , Neurônios/fisiologia , Convulsões/fisiopatologia , Estado Epiléptico/fisiopatologia , Animais , Benzilaminas/toxicidade , Bicuculina/farmacologia , Monoaminas Biogênicas/análise , Cerebelo/metabolismo , Dopamina beta-Hidroxilase/metabolismo , Interações Medicamentosas , Eletroencefalografia , Antagonistas de Aminoácidos Excitatórios/farmacologia , Espaço Extracelular/metabolismo , Lobo Frontal/metabolismo , Antagonistas GABAérgicos , Hipocampo/metabolismo , Hipocampo/patologia , Imuno-Histoquímica , Locus Cerúleo/fisiopatologia , Masculino , Neurotoxinas/toxicidade , Norepinefrina/análise , Norepinefrina/metabolismo , Condutos Olfatórios/metabolismo , Quinoxalinas/farmacologia , Ratos , Ratos Sprague-Dawley , Convulsões/induzido quimicamente , Convulsões/complicações , Convulsões/metabolismo , Coloração e Rotulagem , Estado Epiléptico/induzido quimicamente , Estado Epiléptico/complicações , Estado Epiléptico/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...